[go: up one dir, main page]

MX2018001503A - Derivados de piperazina. - Google Patents

Derivados de piperazina.

Info

Publication number
MX2018001503A
MX2018001503A MX2018001503A MX2018001503A MX2018001503A MX 2018001503 A MX2018001503 A MX 2018001503A MX 2018001503 A MX2018001503 A MX 2018001503A MX 2018001503 A MX2018001503 A MX 2018001503A MX 2018001503 A MX2018001503 A MX 2018001503A
Authority
MX
Mexico
Prior art keywords
bladder
piperazine derivative
receptor
present
detrusor
Prior art date
Application number
MX2018001503A
Other languages
English (en)
Other versions
MX373841B (es
Inventor
Tanabe Daisuke
Moritomo Hiroyuki
Makino Takuya
Sugane Takashi
Mihara Hisashi
Maeno Kyoichi
Shimizu Takafumi
Yamashita Daisuke
Yonetoku Yasuhiro
Asai Norio
Osoda Kazuhiko
Sugasawa Keizo
Hosogai Naomi
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MX2018001503A publication Critical patent/MX2018001503A/es
Publication of MX373841B publication Critical patent/MX373841B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Problema Proporcionar un compuesto que se pueda usar como agonista del receptor MC4. Medio para solucionarlo Los presentes inventores han investigado agonistas del receptor MC4 y han encontrado que un derivado de piperazina tiene acción relacionada con los agonistas, con lo cual se completa la presente invención. Es decir que el derivado de piperazina de la presente invención tiene acción agonista del receptor MC4 y se puede usar como agente para prevenir y/o tratar enfermedades de la vejiga y/o el tracto urinario, en particular, vejiga hipoactiva, vejiga hipotónica, vejiga acontráctil, hipoactividad del detrusor, vejiga neurogénica, falla de la relajación uretral, disinergia detrusor-esfínter uretral externo e hiperpiasia prostática benigna.
MX2018001503A 2015-08-04 2016-08-02 Derivado de piperazina. MX373841B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015154601 2015-08-04
PCT/JP2016/072569 WO2017022733A1 (ja) 2015-08-04 2016-08-02 ピペラジン誘導体

Publications (2)

Publication Number Publication Date
MX2018001503A true MX2018001503A (es) 2018-04-24
MX373841B MX373841B (es) 2020-03-25

Family

ID=57943013

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001503A MX373841B (es) 2015-08-04 2016-08-02 Derivado de piperazina.

Country Status (20)

Country Link
US (1) US10301286B2 (es)
EP (1) EP3333165B1 (es)
JP (1) JP6693520B2 (es)
KR (1) KR20180032585A (es)
CN (1) CN107849018B (es)
AR (1) AR105582A1 (es)
AU (1) AU2016302648A1 (es)
CA (1) CA2995188A1 (es)
CO (1) CO2018002416A2 (es)
ES (1) ES2753227T3 (es)
HK (1) HK1251548A1 (es)
IL (1) IL257264A (es)
MX (1) MX373841B (es)
PH (1) PH12018500239A1 (es)
PL (1) PL3333165T3 (es)
PT (1) PT3333165T (es)
RU (1) RU2731913C2 (es)
SG (1) SG11201800882YA (es)
TW (1) TW201718548A (es)
WO (1) WO2017022733A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10710988B2 (en) * 2016-07-19 2020-07-14 Astellas Pharma Inc. Piperazine derivative
EP3558363A1 (en) 2016-12-21 2019-10-30 Amgen Inc. Anti-tnf alpha antibody formulations
CN112824530A (zh) * 2019-11-20 2021-05-21 中国科学院深圳先进技术研究院 一种hek293f悬浮细胞高效电转染方法
CN116924985A (zh) * 2022-03-29 2023-10-24 山东新时代药业有限公司 一种法舒地尔的制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6911447B2 (en) * 2001-04-25 2005-06-28 The Procter & Gamble Company Melanocortin receptor ligands
US7456184B2 (en) * 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
ES2274201T3 (es) * 2002-01-23 2007-05-16 Eli Lilly And Company Agonistas del receptor de melanocortina.
TW200504033A (en) * 2002-10-23 2005-02-01 Procter & Gamble Melanocortin receptor ligands
WO2004078716A1 (en) * 2003-03-03 2004-09-16 Merck & Co. Inc. Acylated piperazine derivatives as melanocortin-4 receptor agonists
CN1816337A (zh) * 2003-05-01 2006-08-09 帕拉坦技术公司 黑素皮质素受体特异性化合物
WO2005102340A1 (en) * 2003-05-30 2005-11-03 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
WO2005040109A1 (en) 2003-10-22 2005-05-06 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
GB0402492D0 (en) * 2004-02-04 2004-03-10 Pfizer Ltd Pharmaceutically active compounds
AU2005274701A1 (en) * 2004-07-19 2006-02-23 Merck Sharp & Dohme Corp. Acylated piperidine derivatives as melanocortin-4 receptor agonists
US20080234280A1 (en) 2005-08-01 2008-09-25 Mcmurray Gordon Use of Mc4 Receptor Agonist Compounds
CA2624031A1 (en) * 2005-09-30 2007-04-12 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
JP5243274B2 (ja) * 2006-02-23 2013-07-24 ファイザー・リミテッド ４型メラノコルチン受容体アゴニストのピペリジノイルピロリジン
AU2007219236B2 (en) 2006-02-23 2012-06-21 Pfizer Limited Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
WO2008039418A2 (en) 2006-09-27 2008-04-03 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor modulators
CN102171206B (zh) 2008-08-06 2014-06-25 辉瑞股份有限公司 作为mc4激动剂的二氮杂环庚烷和二氮杂环辛烷
KR101919680B1 (ko) 2014-05-29 2018-11-16 미쓰비시 타나베 파마 코퍼레이션 신규한 피롤리딘 화합물 및 멜라노코르틴 수용체 아고니스트로서의 용도

Also Published As

Publication number Publication date
EP3333165A4 (en) 2019-01-09
PH12018500239A1 (en) 2018-08-13
AU2016302648A1 (en) 2018-02-22
US10301286B2 (en) 2019-05-28
SG11201800882YA (en) 2018-03-28
PT3333165T (pt) 2019-10-29
EP3333165B1 (en) 2019-09-18
PL3333165T3 (pl) 2019-12-31
RU2731913C2 (ru) 2020-09-09
JPWO2017022733A1 (ja) 2018-05-31
ES2753227T3 (es) 2020-04-07
TW201718548A (zh) 2017-06-01
US20180230131A1 (en) 2018-08-16
IL257264A (en) 2018-03-29
MX373841B (es) 2020-03-25
HK1251548A1 (zh) 2019-02-01
CO2018002416A2 (es) 2018-06-12
RU2018107711A3 (es) 2019-11-21
CN107849018B (zh) 2021-02-23
CN107849018A (zh) 2018-03-27
JP6693520B2 (ja) 2020-05-13
WO2017022733A1 (ja) 2017-02-09
AR105582A1 (es) 2017-10-18
KR20180032585A (ko) 2018-03-30
CA2995188A1 (en) 2017-02-09
RU2018107711A (ru) 2019-09-05
EP3333165A1 (en) 2018-06-13

Similar Documents

Publication Publication Date Title
CL2021002998A1 (es) Composiciones de arni contra tmprss6 y métodos para su uso (divisional de solicitud n° 03440-2015)
CL2018003588A1 (es) Uso de inhibidores de miostatina y terapias de combinación.
CL2019000107A1 (es) Composiciones de arni contra el componente c5 del complemento y métodos para su uso.(divisional solicitud 201702014)
CL2018000198A1 (es) Composiciones de arni de transtiretina (ttr) y métodos para su uso para el tratamiento o prevencion de enfermedades asociadas con ttr
GT201700150A (es) Derivados de glucagón con estabilidad mejorada
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
MX2017007829A (es) Composicion antimicrobiana.
UY37269A (es) Agonista del receptor de glucocorticoides e inmunoconjugados del mismo
CO2018002416A2 (es) Derivado de piperazina
CL2020002624A1 (es) Formulaciones de inmunoconjugado anti-cd79b estables.
MX2016013280A (es) Composiciones topicas para el alivio del dolor, manufactura y uso.
DOP2015000288A (es) Composiciones de arni de serpina1 y sus métodos de uso.
MX2019000795A (es) Composiciones de limpieza liquidas con sistema antibacteriano y metodo para su fabricacion.
CL2015002571A1 (es) Composiciones y métodos para le diagnostico y tratamiento del cáncer hepático.
CL2016000055A1 (es) Métodos para tratar o prevenir afecciones oftalmológicas
AR100088A1 (es) Fluido de tratamiento
UY36373A (es) Compuestos para usarse en el tratamiento antihelmíntico
CO2017001842A2 (es) Artículo y método para mantener el flujo menstrual dentro de la vagina
MX2017011018A (es) Inhibicion de la actividad de olig2.
AR103323A1 (es) Derivados de glucagón
UY36196A (es) Compuestos para usar en el tratamiento antihelmíntico
MX2016007803A (es) Composiciones de acidos grasos omega 3 para tratar enfermedades que implican daños al sistema nervioso.
MX2019002259A (es) Inhibicion de la actividad de la olig2.
UY35695A (es) Composicion para el tratamiento contra el envejecimiento de la piel

Legal Events

Date Code Title Description
FG Grant or registration